FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies

Wanqing Wang; Kaipeng Jiang; Xue Liu; Ju Li; Wenshuo Zhou; Chang Wang; Jiuwei Cui; Tingting Liang

doi:10.3389/fphar.2023.1278056

FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies

Front Pharmacol. 2023 Nov 13:14:1278056. doi: 10.3389/fphar.2023.1278056. eCollection 2023.

Authors

Wanqing Wang¹, Kaipeng Jiang¹, Xue Liu¹, Ju Li¹, Wenshuo Zhou¹, Chang Wang¹, Jiuwei Cui¹, Tingting Liang¹

Affiliation

¹ Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.

Abstract

Drug therapy, including chemotherapy, targeted therapy, immunotherapy, and endocrine therapy, stands as the foremost therapeutic approach for contemporary human malignancies. However, increasing drug resistance during antineoplastic therapy has become a substantial barrier to favorable outcomes in cancer patients. To enhance the effectiveness of different cancer therapies, an in-depth understanding of the unique mechanisms underlying tumor drug resistance and the subsequent surmounting of antitumor drug resistance is required. Recently, F-box and WD Repeat Domain-containing-7 (FBXW7), a recognized tumor suppressor, has been found to be highly associated with tumor therapy resistance. This review provides a comprehensive summary of the underlying mechanisms through which FBXW7 facilitates the development of drug resistance in cancer. Additionally, this review elucidates the role of FBXW7 in therapeutic resistance of various types of human tumors. The strategies and challenges implicated in overcoming tumor therapy resistance by targeting FBXW7 are also discussed.

Keywords: Fbxw7; drug resistance; human tumors; targeted therapy; ubiquitin-proteasome system (UPS).

Publication types

Review

Grants and funding

The authors declare that the financial support was received for the research, authorship, and/or publication of this article. This study was funded by Jilin Provincial Education Department (Ref: 3D5196778428), and Jilin Provincial Finance Department (Ref: 3D5214495428). This work was supported from the First Hospital of Jilin University.